Zacks small cap research.

Zacks Premium Research for ZSCCX View All Zacks Mutual Fund Rank #1's View the Zacks Mutual Fund Rank Guide Annual Return * 1 = Top 20%, 5 = Bottom 20% …Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers.The small-cap index Russell 2000 recently witnessed its most impressive week in over two years as investors bet on the Federal Reserve's halt in its interest rate …By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics,

A conference call was also held to discuss results with investors. For the third quarter of 2023 ending September 30, 2023 and versus the prior year’s third quarter, no revenues were recognized. Net loss for the third quarter totaled ($73.5) million or ($4.89) per share. Operational expenses rose 67% over 3Q:23 levels as increases related to ...

Zacks Equity Research December 04, 2023. Better trading ... Ahead of today’s normal trading session, only the small-cap Russell 2000 is in the green at this …David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.Zacks Small Cap Research. PLX: Back of the Envelope. Read full article. 1. Zacks Small Cap Research. May 30, 2023 at 8:00 AM ...By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.

OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ...

The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Find top rated mutual funds and information to help you beat the market. Explore mutual fund resources, portfolios, and mutual fund commentary at Zacks.When you start getting deeper into the world of investing, you’ll begin learning an entirely new, finance-specific vocabulary. From assets and mutual funds to expense ratios and the New York Stock Exchange, there’s certainly a lot to absorb...© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)In recent years, the topic of energy prices has become increasingly important for consumers. With rising concerns about affordability and fair pricing, governments around the world have implemented measures to protect consumers from excessi...Nov 13, 2023 · By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatmentsThe following slide gives an overview of the planned early stage clinical trials for CF-370 following submission of the IND, which we expect to occur in the third quarter of 2023. While a Phase 2 proof-of-concept trial is currently planned in patients with cystic fibrosis, the broad spectrum activity of CF-370 means it could likely be used for ...Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...Nov 13, 2023 · By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

Genasys (. GNSS Quick Quote. GNSS - Free Report) has an Earnings ESP of +21.74% and a Zacks Rank #2. GNSS is scheduled to release fourth-quarter fiscal 2023 …Mar 31, 2023 · In 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By David Bautz, PhD. NASDAQ:QLGN. READ THE FULL QLGN RESEARCH REPORT. Business Update . Preclinical Data on QN-302 Presented at AACR Conference on Pancreatic Cancer . In September 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced the presentation of two posters on QN-302 at the AACR 8 th Special Conference on Pancreatic Cancer.Nov 27, 2023 · 06/12/2023. UHAL: U-Haul Holding Company Reports Financial Results for Fiscal 2023; Demand for truck rentals slowed in the second half of FY2023. Management aspires to hold the market share gains and has expectations that the self-moving market will stabilize in FY2024. 06/08/2023. Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE. _____ 1. The 0.68 Hazard Ratio was better than and below the pre-specified cutoff of 0.721. 2. Compiled by Zacks’ analysts from company press …

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update In-House Research Capabilities Bolstered Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has increased its in-house research capabilities with the purchase, construction, and planned construction of multiple research centers. These facilities will allow the company to have better control over the early

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

TOL Quick Quote. TOL. 81.27. +9.45%. Compare funds in the Small-Cap-ETFs. Compare similar funds using our ETF Categories. Zacks Investment Research. Our Research, Your Success.By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinuedZacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our process The Zacks Small-Cap... Zacks Investment Research has three different main subscription plans: Zacks Premium, Zacks Investor Collection, and Zacks Ultimate. Zacks Premium costs …Nov 15, 2023 · The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ... Nov 18, 2022 · OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ... Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...In a March 28, 2023 press release, Allarity announced updates to its Phase II programs that are evaluating Ixempra and stenoparib as monotherapies. The pace of recruitment for both trials has been slow due to impacts from the pandemic and from on-site personnel staffing. To address the issue, Allarity has engaged additional contract research ...

Zacks Small-Cap Research Spo nsored – Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 30, 2022 Lisa Thompson 312-265-9154 / [email protected] ... Zacks Inves tment Research Page 3 scr.zacks.com mainly related to capital markets consulting fees incurred as Tenet plans to list its ...Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Screenshot of interview with Allarity CEO, Jim Cullem. 2.The Zacks Small/Mid Cap Core Portfolio (SMIZ) ETF represents the combination of our Small and Mid Cap separately managed accounts (SMAs), drawing upon over a decade of comprehensive research and analysis. Utilizing the Zacks Proprietary Multi-factor Alpha Model, our portfolio management team identifies a selection of the …May 22, 2023 · By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ... Instagram:https://instagram. t206 honus wagner cardubiquiti inc.books day tradingcigna dental savings plans Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ... Nov 16, 2023 · Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ... what is a half a dollar worthmbs market Oct 31, 2023 · $31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three... companies like legal shield SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …INXDF: INXDF is Changing the Digital Financial World. INX Digital (OTCQB:INXDF) is a company that provides a regulated platform where verified customers can trade cryptocurrencies and security tokens on a secure and around the clock basis. The security token market appears poised to explode and INX is the only company to this …